Big Pharma’s business-as-usual playbook relies on egregious pricing practices and rhetoric designed to set and keep drug prices high.

Drug prices in the United States are out of control as a direct result of the egregious pricing and anti-competitive practices of brand name pharmaceutical companies. Rising prescription drug prices threaten the affordability of our health care system, the long-term health of our nation and the vitality of our entire economy. Public opinion research finds as many as one-in-three Americans experience financial difficulty, either as a patient themselves or through a family member, affording prescription drugs. CSRxP has developed market-based solutions to restore a functioning market and lower prices for patients by increasing list price transparency, promoting competition and actual innovation and focusing on better value for patients, not better value for pharmaceutical companies.

Sep 17, 2025

THEY SAID IT!: FDA COMMISSIONER: BIG PHARMA’S BILLIONS OF DOLLARS SPENT ON DTC ADVERTISING “WOULD BE BETTER SPENT ON LOWERING DRUG PRICES”

Makary Highlights and Adds to Momentum “Across the Political Spectrum” to Hold Brand

Sep 17, 2025

U.S. HOUSE COMMITTEE SHOULD ADVANCE Q1/Q2 REFORMS TO PROMOTE GREATER COMPETITION AND HELP LOWER PRESCRIPTION DRUG PRICES

Lawmakers Should Advance Bipartisan, Market-Based Solution to Crack Down on

Sep 10, 2025

DOSE OF REALITY: GENERIC AND BIOSIMILAR COMPETITION GENERATES SIGNIFICANT SAVINGS FOR PATIENTS AND THE U.S. HEALTH CARE SYSTEM

Report Underscores How Competition Lowers Prescription Drug Prices by Providing More

Sep 3, 2025

DOSE OF REALITY: STUDY FINDS BIG PHARMA’S PATENT THICKETS ON JUST FOUR BRAND NAME DRUGS COST MORE THAN $3.5 BILLION IN TWO YEARS

Patent Abuse Blocked Competition From More Affordable Alternatives For Periods Ranging

Sep 17, 2025

THEY SAID IT!: FDA COMMISSIONER: BIG PHARMA’S BILLIONS OF DOLLARS SPENT ON DTC ADVERTISING “WOULD BE BETTER SPENT ON LOWERING DRUG PRICES”

Makary Highlights and Adds to Momentum “Across the Political Spectrum” to Hold Brand

Sep 17, 2025

U.S. HOUSE COMMITTEE SHOULD ADVANCE Q1/Q2 REFORMS TO PROMOTE GREATER COMPETITION AND HELP LOWER PRESCRIPTION DRUG PRICES

Lawmakers Should Advance Bipartisan, Market-Based Solution to Crack Down on

Sep 10, 2025

DOSE OF REALITY: GENERIC AND BIOSIMILAR COMPETITION GENERATES SIGNIFICANT SAVINGS FOR PATIENTS AND THE U.S. HEALTH CARE SYSTEM

Report Underscores How Competition Lowers Prescription Drug Prices by Providing More

Sep 3, 2025

DOSE OF REALITY: STUDY FINDS BIG PHARMA’S PATENT THICKETS ON JUST FOUR BRAND NAME DRUGS COST MORE THAN $3.5 BILLION IN TWO YEARS

Patent Abuse Blocked Competition From More Affordable Alternatives For Periods Ranging

Videos

Watch and learn about Big Pharma’s price-gouging techniques that are the cause of out-of-control drug prices.

Fact Sheets

Get the facts on Big Pharma’s anti-competitive tactics, like price-gouging and patent abuse that keeps drug prices high.

Infographics

Learn about how Big Pharma is driving the Rx drug pricing crisis with our infographics.

Polling

See recent surveys on American voters’ opinions on Big Pharma’s blame game and out-of-control drug pricing.

Join us in telling lawmakers: It’s time to hold Big Pharma accountable and lower Rx drug prices.

By signing your name, you are opting-in to receive calls and SMS/MMS messages, including autodialed and automated calls and texts, to that number from CSRxP. Msg & data rates may apply.
This field is for validation purposes and should be left unchanged.